ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0420

What Does It Mean – A Good Response to NSAIDs? A Systematic Comparison of Patients with Axial Spondyloarthritis and Controls with Chronic Back Pain

Xenofon Baraliakos1, Imke Redeker2, Elena Bergmann3, Styliani Tsiami4 and Juergen Braun5, 1Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 2Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Bochum, Germany, 3Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 4Rheumazentrum Ruhrgebiet, Herne, Ruhr-University Bochum, Herne, Germany, 5Rheumazentrum Ruhrgebiet, Herne, Germany

Meeting: ACR Convergence 2022

Keywords: Back pain, Nonsteroidal antiinflammatory drugs (NSAIDs), spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Spondyloarthritis Including PsA – Treatment Poster I: AxSpA

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: A fast response to NSAIDs is an important finding in the evaluation of clinical findings within the items comprising the ASAS classification criteria but also for the treatment decision for escalation to a bDMARD in patients with axial spondyloarthritis (axSpA). However, the differentiation of NSAID responses between patients with axSpA and degenerative or unspecific back pain is still unclear. We studied the differences in the velocity and magnitude of NSAID response velocity in patients with established bDMARD naïve axSpA vs. patients with other, non-inflammatory reasons of back pain.

Methods: Patients with axSpA without degenerative reasons for back pain or patients with degenerative or unspecific back pain presenting due to high levels of back pain (NRS≥4/10) were consecutively recruited. Assessments included clinical examination, laboratory tests and MRI of the lumbar spine. Previous NSAID intake was allowed only if it was taken in low doses without showing a clinical response, otherwise patients were NSAID naïve. Upon study inclusion, patients were treated with the maximum possible dose of an NSAID that they have reported to tolerate in lower doses in the past, independent of whether this was a Cox-2 inhibitor or a non-coxib. Assessment of response was performed using a standardized questionnaire after 2, 6, 12, 24, 36, 48 hours and after 1, 2 and 4 weeks. Any NSAID response was defined as improvement of pain >2/10 points and a good response to NSAIDs as an improvement >50% from the initial status.

Results: A total of 68 patients with axSpA, 107 patients with degenerative back pain and 58 patients with unspecific back pain were included. The mean age was 42.7±10.7, 51.2±11.3, and 45.8±10.0 years, the main symptom duration 15.1±11.1, 16.1±12.6, and 11.9 ±10.1 years and the proportion of males was 57.4%, 19.6%, and 19.0% respectively. Inflammatory back pain was reported by 42 (75%), 48 (57.8%), and 29 (60.4%) patients, respectively and the mean pain score was 6.2±2.3, 6.7±1.8, and 6.2±1.8, respectively. In axSpA, the mean BASDAI and BASFI scores were 5.5±1.8 and 4.5±2.5, respectively. There was no difference in the cumulative response to NSAIDs between all three diagnoses, with an overall proportion of 27%-30% of patients showing improvement. However, better but not faster responses were found for the subgroups of patients with nr-axSpA (Fig. 1) and for the male patients in the entire axSpA group, while axSpA patients with systemic inflammatory activity defined by increased CRP showed lower rates of response as compared to non-inflammatory reasons of back pain diagnoses. All other subanalyses did not reveal any differences between axSpA patients and other non-inflammatory reasons of back pain.

Conclusion: In this prospective evaluation, the generally proposed better response of axSpA patients to treatment with high doses of NSAIDs as compared with non-inflammatory back pain was not confirmed, although the overall rate of responders was similar to previously reported rates. On the other hand, better responses were found in patients treated in the early (nr-axSpA) stage and in male patients. axSpA patients with increased CRP values showed lower rates of response.

Supporting image 1


Disclosures: X. Baraliakos, AbbVie, Lilly, Galapagos, MSD, Novartis, Pfizer, UCB, Bristol-Myers Squibb, Janssen, Roche, Sandoz, Sanofi; I. Redeker, None; E. Bergmann, None; S. Tsiami, None; J. Braun, None.

To cite this abstract in AMA style:

Baraliakos X, Redeker I, Bergmann E, Tsiami S, Braun J. What Does It Mean – A Good Response to NSAIDs? A Systematic Comparison of Patients with Axial Spondyloarthritis and Controls with Chronic Back Pain [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/what-does-it-mean-a-good-response-to-nsaids-a-systematic-comparison-of-patients-with-axial-spondyloarthritis-and-controls-with-chronic-back-pain/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/what-does-it-mean-a-good-response-to-nsaids-a-systematic-comparison-of-patients-with-axial-spondyloarthritis-and-controls-with-chronic-back-pain/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology